Tag: Proarrhythmia

According to the Cardiac Arrhythmia Suppression Trial (CAST), flecainide use was associated with increased mortality in patients with recent myocardial infarction. This highlights the serious nature of its adverse effects, prompting a need to understand exactly what is the adverse effect of flecainide and why careful patient selection and monitoring are paramount.

While flecainide is an effective antiarrhythmic medication for managing conditions like atrial fibrillation (AFib), it carries a notable risk of causing a different arrhythmia, known as atrial flutter. This paradoxical effect, often referred to as proarrhythmia, is a critical consideration in clinical practice and for patients undergoing treatment. Understanding the mechanism and risk factors for flecainide-induced atrial flutter is vital for safe and effective arrhythmia management.